1 | | = Temp = |
| 1 | CCAP |
| 2 | |
| 3 | logged in as longkr |
| 4 | Logout |
| 5 | PreferencesHelp/GuideAbout Trac |
| 6 | HomeResearchCommunicationTeachingTimelineBrowse sourceSearch |
| 7 | wiki:Research/DesignStudy/SteeringGroup/2020-09-24 |
| 8 | UpStart pageIndexHistory |
| 9 | LhARA Steering Group meeting #4 |
| 10 | 24th September 2020 10:00 GMT |
| 11 | |
| 12 | Notes |
| 13 | |
| 14 | Notes of last meeting and actions arising: |
| 15 | KL: Set up series of meetings with leads at partner organisations to discuss preparation of R&D programme. |
| 16 | Superceded. |
| 17 | KL/CB: Consider meeting between Imperial (and other) ion-accelerator experts with the relevant experts in CLF. |
| 18 | Ongoing. |
| 19 | KL/KK: to collaborate on the development for a proposal for such a meeting on the timescale of November 2020. |
| 20 | Ongoing. |
| 21 | KL: Ensure one representative per group at the next LhARA SG meeting. |
| 22 | Stands. |
| 23 | KL: Raise NIHR engagement with K.Gleeson. |
| 24 | Done. |
| 25 | KL: Seek PPI representative for SG. |
| 26 | Done. Welcome G. Jones and H. Hall. |
| 27 | KK, JPar, CW, KL: Make relevant contact with local PPI groups as described in item 4. |
| 28 | StG: Brm is not a radiotherapy research centre. Shoudl contact Manchester, Oxford, and Liverpool. |
| 29 | TG: Also need to contact with relevant medical physics groups. |
| 30 | KL&JPar: Write to CTRAD w/s 4 chair (KK) to ask how we might work together to raise awarenents of our programme among the patient and clinician communitites. |
| 31 | Done. Letter written and sent, see under clinician engagement below. Revised action needs to be agreed. |
| 32 | KK, JPar, CW, KL, SG: Make relevant contact with local clinician groups as described in item 4. |
| 33 | Ongoing. |
| 34 | KL: Write to J.Clarke to ask for support to reach out to relevant industry. |
| 35 | Stands. |
| 36 | PA: Make contact with MTC to see how to make contact with relevant industry. |
| 37 | Stands |
| 38 | PA/KL will cooperate in drafting a letter. |
| 39 | Stands. |
| 40 | KL: Review proposed w/p structure and skills matrix taking into account comments under item 4. |
| 41 | Stands. |
| 42 | KL/RMcL: Liaise to generate small group to coordinate development of instrumentation aspects of the programme. |
| 43 | Done. Meeting organised between A.Price and R.McLauchlan a success. |
| 44 | Update on progress: KL |
| 45 | Towards a PPI strategy for LhARA: GJ, HH |
| 46 | Main stem of strategy is to raise awareness with public and with patients. Then develop the engagement as the programme progresses. |
| 47 | Hard to see anything which would not benefit patients and also the health services. Patient input is vital all at all stages in the development of the programme. |
| 48 | Management of PPI will take time. Perhaps means that we need to include some resource. Marsden PPI outreach. |
| 49 | HH sits on various PPI advisory groups and can make links top various institutes. |
| 50 | Focus on engagement rather than involvement. |
| 51 | StG: |
| 52 | Agrees re effort involved in getting broad activity. Link to the Royal Marsden will be important. |
| 53 | KK: |
| 54 | BRC links important. |
| 55 | SG expressed it grateful recognition of the efforts of GJ and HH and the PPI representatives in drafting the two Lay Summaries so far. Both are/will be published. |
| 56 | Towards a clinician-engagement strategy for LhARA: StG |
| 57 | Neil Burnett and Adrian Crellin from Brm meeting might be pursuared to promote activity. Elizabeth Schuster, Rostoc is a researcher into the impact of microbeams. |
| 58 | There is a need to reach out to research-active clinicians. Probably should build up a target list in preparation for a webinar. A process such as that adopted by TP for the endstation/diagnostics development would be appropriate. |
| 59 | KK: |
| 60 | Noted the perception in the community that laser-ion beams are like nuclear fusion -- always 15 years away. |
| 61 | Critical to develop clear statement of what what the laser-hybrid technique can do that others cant. |
| 62 | Meeting: |
| 63 | We agreed to work towards a meeting of the relevant peer groups. TKW agreed to make contact with IoP at "top level". |
| 64 | Transformative Healthcare Technologies second call: KL/All |
| 65 | Updated outline presented at the LhARA weekly meeting 22Sep20 |
| 66 | Discussion included: |
| 67 | PPI: GJ/HH |
| 68 | Clinician engagement: StG |
| 69 | Plan for preparation of proposal |
| 70 | Scope |
| 71 | Work packages |
| 72 | Stakeholders |
| 73 | DONMs |
| 74 | TBD |
| 75 | AoB |
| 76 | Agenda |
| 77 | |
| 78 | Notes of last meeting and actions arising: |
| 79 | KL: Set up series of meetings with leads at partner organisations to discuss preparation of R&D programme. |
| 80 | Superceded. |
| 81 | KL/CB: Consider meeting between Imperial (and other) ion-accelerator experts with the relevant experts in CLF. |
| 82 | Ongoing. |
| 83 | KL/KK: to collaborate on the development for a proposal for such a meeting on the timescale of November 2020. |
| 84 | Ongoing. |
| 85 | KL: Ensure one representative per group at the next LhARA SG meeting. |
| 86 | Stands. |
| 87 | KL: Raise NIHR engagement with K.Gleeson. |
| 88 | Done. |
| 89 | KL: Seek PPI representative for SG. |
| 90 | Done. Welcome G. Jones and H. Hall. |
| 91 | KK, JPar, CW, KL: Make relevant contact with local PPI groups as described in item 4. |
| 92 | KL&JPar: Write to CTRAD w/s 4 chair (KK) to ask how we might work together to raise awarenents of our programme among the patient and clinician communitites. |
| 93 | Done. Letter written and sent, see under clinician engagement below. Revised action needs to be agreed. |
| 94 | KK, JPar, CW, KL, SG: Make relevant contact with local clinician groups as described in item 4. |
| 95 | Ongoing. |
| 96 | KL: Write to J.Clarke to ask for support to reach out to relevant industry. |
| 97 | Stands. |
| 98 | PA: Make contact with MTC to see how to make contact with relevant industry. PA/KL will cooperate in drafting a letter. |
| 99 | KL: Review proposed w/p structure and skills matrix taking into account comments under item 4. |
| 100 | Stands.&& |
| 101 | KL/RMcL: Liaise to generate small group to coordinate development of instrumentation aspects of the programme. |
| 102 | Done. Meeting organised between A.Price and R.McLauchlan a success. |
| 103 | Update on progress: KL |
| 104 | Towards a PPI strategy for LhARA: GJ, HH |
| 105 | Towards a clinician-engagement strategy for LhARA: StG |
| 106 | Transformative Healthcare Technologies second call: KL/All |
| 107 | Updated outline presented at the LhARA weekly meeting 22Sep20 |
| 108 | Discussion to include: |
| 109 | PPI |
| 110 | Clinician engagement: |
| 111 | Industrial engagement: |
| 112 | Plan for preparation of proposal |
| 113 | Scope |
| 114 | Work packages |
| 115 | Stakeholders |
| 116 | Next steps discussion |
| 117 | DONMs |
| 118 | TBD |
| 119 | AoB |
| 120 | Last modified 26 seconds ago |
| 121 | Attachments (4) |
| 122 | |
| 123 | |
| 124 | Download in other formats: |
| 125 | Plain text |
| 126 | Trac PoweredPowered by Trac 1.0.13 |
| 127 | By Edgewall Software.Visit the Trac open source project at |
| 128 | http://trac.edgewall.org/ |